Description
Olaparib, marketed under the brand name LYNPARZA, It is an prescription medication that has been approved olaparib (Lynparza) for several uses at different times:
High-risk early breast cancer
The FDA approved olaparib on March 11, 2022 for the adjuvant treatment of high-risk early breast cancer.
Ovarian cancer
The FDA approved olaparib on August 17, 2017 for the maintenance treatment of adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The FDA also approved olaparib monotherapy on December 19, 2018 for the first-line maintenance treatment of BRCA-mutated advanced ovarian cancer.
What is LYNPARZA (olaparib) ?
LYNPARZA (olaparib) tablets, for oral use. U.S. Approval: 2014
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
Ovarian cancer
- for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. • for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Breast cancer
- in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
How to order approved “LYNPARZA (olaparib) for Tablets” Medicine?
LYNPARZA (Olaparib) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing LYNPARZA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.